位置:首页 > 蛋白库 > KAX6L_UROYA
KAX6L_UROYA
ID   KAX6L_UROYA             Reviewed;          62 AA.
AC   P0DL37; A0A0A0PP69;
DT   01-OCT-2014, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2014, sequence version 1.
DT   25-MAY-2022, entry version 20.
DE   RecName: Full=Potassium channel toxin alpha-KTx 6.21 {ECO:0000303|PubMed:24723491};
DE   AltName: Full=Urotoxin {ECO:0000303|PubMed:24723491, ECO:0000303|PubMed:31881193};
DE            Short=Uro {ECO:0000303|PubMed:31881193};
DE   Flags: Precursor;
OS   Urodacus yaschenkoi (Inland robust scorpion).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Chelicerata; Arachnida;
OC   Scorpiones; Iurida; Scorpionoidea; Scorpionidae; Urodacinae; Urodacus.
OX   NCBI_TaxID=1273102;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 25-43, FUNCTION, MASS
RP   SPECTROMETRY, AMIDATION AT VAL-61, 3D-STRUCTURE MODELING IN INTERACTION
RP   WITH KV1.1/KCNA1 AND KV1.2/KCNA2, MOLECULAR DYNAMICS SIMULATIONS, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Venom, and Venom gland;
RX   PubMed=24723491; DOI=10.1124/mol.113.090183;
RA   Luna-Ramirez K., Bartok A., Restano-Cassulini R., Quintero-Hernandez V.,
RA   Coronas F.I.V., Christensen J., Wright C.E., Panyi G., Possani L.D.;
RT   "Structure, molecular modeling, and function of the novel potassium channel
RT   blocker urotoxin isolated from the venom of the Australian scorpion
RT   Urodacus yaschenkoi.";
RL   Mol. Pharmacol. 86:28-41(2014).
RN   [2]
RP   STRUCTURE BY NMR OF 25-61, FUNCTION, DISULFIDE BONDS, RECOMBINANT
RP   EXPRESSION, AND MUTAGENESIS OF THR-43 AND LYS-49.
RX   PubMed=31881193; DOI=10.1016/j.bcp.2019.113782;
RA   Luna-Ramirez K., Csoti A., McArthur J.R., Chin Y.K.Y., Anangi R.,
RA   Najera R.D.C., Possani L.D., King G.F., Panyi G., Yu H., Adams D.J.,
RA   Finol-Urdaneta R.K.;
RT   "Structural basis of the potency and selectivity of Urotoxin, a potent Kv1
RT   blocker from scorpion venom.";
RL   Biochem. Pharmacol. 174:113782-113782(2020).
CC   -!- FUNCTION: Reversible blocker of voltage-gated potassium channels with
CC       fast binding and unbinding kinetics (PubMed:24723491, PubMed:31881193).
CC       Has highest activity on human voltage-gated potassium channel
CC       Kv1.2/KCNA2 channels (IC(50)=0.11-0.16 nM), whereas its affinity for
CC       other channels tested was in the nanomolar range (hKv1.1/KCNA1,
CC       IC(50)=253 nM; hKv1.3/KCNA3, IC(50)=91 nM; and hKCa3.1/KCNN4, IC(50)=70
CC       nM) (PubMed:24723491, PubMed:31881193). {ECO:0000269|PubMed:24723491,
CC       ECO:0000269|PubMed:31881193}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:24723491}.
CC   -!- TISSUE SPECIFICITY: Expressed by the venom gland.
CC       {ECO:0000305|PubMed:24723491}.
CC   -!- DOMAIN: Has the structural arrangement of an alpha-helix connected to
CC       antiparallel beta-sheets by disulfide bonds (CS-alpha/beta).
CC       {ECO:0000305}.
CC   -!- PTM: C-terminal amidation is important for activity. There is a 50-70-
CC       fold decrease in ability to inhibit Kv1.2/KCNA2 when the toxin is not
CC       amidated. This decrease may be explained by a 23-fold slower
CC       association rate (k(on)) together with a 2-fold faster dissociation
CC       rate (k(off)). {ECO:0000269|PubMed:31881193}.
CC   -!- MASS SPECTROMETRY: Mass=4012.75; Method=Electrospray;
CC       Evidence={ECO:0000269|PubMed:24723491};
CC   -!- MISCELLANEOUS: Has no effect on hKv1.4/KCNA4, hKv1.5/KCNA5, ether-a-go-
CC       go-related gene type 1 (hERG1), and ether-a-go-go-like (hELK2)
CC       channels. {ECO:0000305|PubMed:24723491}.
CC   -!- SIMILARITY: Belongs to the short scorpion toxin superfamily. Potassium
CC       channel inhibitor family. Alpha-KTx 06 subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; KC818423; AHJ59315.1; -; mRNA.
DR   PDB; 6MZT; NMR; -; A=25-61.
DR   PDBsum; 6MZT; -.
DR   AlphaFoldDB; P0DL37; -.
DR   SMR; P0DL37; -.
DR   TCDB; 8.B.8.1.7; the Alpha-ktx15 scorpion toxin (Alpha-ktx15) family.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0008200; F:ion channel inhibitor activity; IEA:InterPro.
DR   GO; GO:0015459; F:potassium channel regulator activity; IEA:UniProtKB-KW.
DR   GO; GO:0090729; F:toxin activity; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.30.10; -; 1.
DR   InterPro; IPR036574; Scorpion_toxin-like_sf.
DR   InterPro; IPR001947; Scorpion_toxinS_K_inh.
DR   Pfam; PF00451; Toxin_2; 1.
DR   PRINTS; PR00286; CHARYBDTOXIN.
DR   SUPFAM; SSF57095; SSF57095; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Amidation; Direct protein sequencing; Disulfide bond;
KW   Ion channel impairing toxin; Neurotoxin; Potassium channel impairing toxin;
KW   Secreted; Signal; Toxin.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000269|PubMed:24723491"
FT   PEPTIDE         25..61
FT                   /note="Potassium channel toxin alpha-KTx 6.21"
FT                   /evidence="ECO:0000269|PubMed:24723491"
FT                   /id="PRO_0000430422"
FT   SITE            49
FT                   /note="Pharmacophore, responsible of Kv1 potassium channel
FT                   pore occlusion"
FT                   /evidence="ECO:0000269|PubMed:31881193"
FT   MOD_RES         61
FT                   /note="Valine amide"
FT                   /evidence="ECO:0000269|PubMed:24723491"
FT   DISULFID        29..50
FT                   /evidence="ECO:0000269|PubMed:31881193,
FT                   ECO:0007744|PDB:6MZT"
FT   DISULFID        35..55
FT                   /evidence="ECO:0000269|PubMed:31881193,
FT                   ECO:0007744|PDB:6MZT"
FT   DISULFID        39..57
FT                   /evidence="ECO:0000269|PubMed:31881193,
FT                   ECO:0007744|PDB:6MZT"
FT   DISULFID        45..60
FT                   /evidence="ECO:0000269|PubMed:31881193,
FT                   ECO:0007744|PDB:6MZT"
FT   MUTAGEN         43
FT                   /note="T->Q: 30-fold decrease in ability to inhibit
FT                   Kv1.1/KCNA1, and no change in ability to inhibit both
FT                   Kv1.2/KCNA2 and Kv1.3/KCNA3 potassium channels."
FT                   /evidence="ECO:0000269|PubMed:31881193"
FT   MUTAGEN         49
FT                   /note="K->A: Very important decrease in ability to inhibit
FT                   Kv1.2/KCNA2 potassium channel, and important decrease in
FT                   ability to inhibit both Kv1.1/KCNA1 and Kv1.3/KCNA3
FT                   potassium channels."
FT                   /evidence="ECO:0000269|PubMed:31881193"
FT   STRAND          30..32
FT                   /evidence="ECO:0007829|PDB:6MZT"
FT   HELIX           33..42
FT                   /evidence="ECO:0007829|PDB:6MZT"
FT   STRAND          48..51
FT                   /evidence="ECO:0007829|PDB:6MZT"
FT   STRAND          54..57
FT                   /evidence="ECO:0007829|PDB:6MZT"
SQ   SEQUENCE   62 AA;  6793 MW;  0BB389DFF032AC2F CRC64;
     MNAKLIYLLL VVTTMMLTFD TTQAGDIKCS GTRQCWGPCK KQTTCTNSKC MNGKCKCYGC
     VG
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024